Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 3/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 5/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | SCD | O00767 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5161199 | 0.93 | ALDH1A1 (0.44) | MAPTALDH1A1SMN1; SMN2HTTHSP90AA1 | |
| SCHEMBL4815288 | 0.91 | MAPT (0.41) | MAPTALDH1A1SMN1; SMN2HTTHSP90AA1 | |
| SCHEMBL3424653 | 0.83 | PDE2A (0.45) | MAPTALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL8917364 | 0.81 | LMNA (0.44) | MAPTALDH1A1SMN1; SMN2HTTMEN1 | |
| SCHEMBL8486163 | 0.77 | ALDH1A1 (0.43) | MAPTALDH1A1HTTMEN1KMT2A | |
| SCHEMBL15341363 | 0.76 | LMNA (0.43) | MAPTALDH1A1SMN1; SMN2HTTMEN1 | |
| SCHEMBL4821392 | 0.76 | KMT2A (0.44) | MAPTALDH1A1SMN1; SMN2HTTMEN1 | |
| SCHEMBL3424814 | 0.75 | PDE2A (0.46) | MAPTALDH1A1SMN1; SMN2HTTMEN1 | |
| SCHEMBL5593378 | 0.74 | PDE2A (0.42) | MAPTALDH1A1SMN1; SMN2HTTMEN1 | |
| SCHEMBL5228613 | 0.74 | LMNA (0.48) | MAPTALDH1A1SMN1; SMN2HTTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020068744-A1 | Substituted-triazolopyrimidines as anticancer agents | AMERICAN HOME PRODUCTS CORPORATION | 2002-06-06 | — | — | US | claimed |
| US-7329663-B2 | Substituted-triazolopyrimidines as anticancer agents | WYETH (US) | 2008-02-12 | — | — | US | disclosed |
| US-20020068744-A1 | Substituted-triazolopyrimidines as anticancer agents | AMERICAN HOME PRODUCTS CORPORATION | 2002-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020068744-A1 | Substituted-triazolopyrimidines as anticancer agents | TUBB3, TUBA1C, TUBB1 | MAPT 56/4885ALDH1A1 2231/4885SMN1; SMN2 655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.